- Home
- SRDX
SRDX
Surmodics Inc.
as 12-18-2024 12:43pm EST
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | EDEN PRAIRIE |
| Market Cap: | 562.6M | IPO Year: | 1998 |
| Target Price: | $43.00 | AVG Volume (30 days): | 171.3K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.17 - $42.44 | Next Earning Date: | 01-30-2025 |
| Revenue: | $126,078,000 | Revenue Growth: | -4.91% |
| Revenue Growth (this year): | 13.75% | Revenue Growth (next year): | 13.67% |
Stock Insider Trading Activity of Surmodics Inc. (SRDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Arens Timothy J. | SRDX | Chief Financial Officer | Nov 26 '24 | Sell | $39.44 | 7,009 | $276,453.18 | 70,350 |
Latest Surmodics Inc. News
SRDX Breaking Stock News: Dive into SRDX Ticker-Specific Updates for Smart Investing
Zacks
12 days ago
Why Is SurModics (SRDX) Up 4% Since Last Earnings Report?
TipRanks
a month ago
SurModics Inc. Faces Legal Hurdles: Shareholder Lawsuits Threaten Merger and Financial Stability
Zacks
a month ago
SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why
Zacks
a month ago
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
Zacks
a month ago
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
Associated Press Finance
a month ago
SurModics: Fiscal Q4 Earnings Snapshot
Business Wire
a month ago
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Business Wire
2 months ago
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
Compare SRDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRDX Surmodics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.